• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $6,894 Mln
  • Price to Earnings Ratio price-to-earning 18.13
  • 12 Month Earnings monthly-earning $321 Mln

Jazz Pharmaceuticals PLC (JAZZ) Share Price

$110.58

As on 12-Apr-2024 16:08 EDT

up-down-arrow $-2.91-2.56%

  • Prev Close info

    $113.49

  • Day's Openinfo

    $113.10

  • Today's Highinfo

    $113.10

  • Today's Lowinfo

    $110.42

  • Today's Volumeinfo

    429,348

  • 52 Week rangeinfo

    $110.42 - 147.14

Please wait...

Jazz Pharmaceuticals PLC (JAZZ) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Jazz Pharmaceuticals PLC (JAZZ)
-10.10 -5.19 -8.16 -24.60 -11.84 -4.58 -1.50
S&P BSE Sensex
2.77 1.01 3.52 23.42 14.40 13.97 12.62
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 12-Apr-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Jazz Pharmaceuticals PLC (JAZZ)
-22.79 25.05 -22.81 10.56 20.43 -7.90 23.50
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Jazz Pharmaceuticals PLC (JAZZ) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Jazz Pharmaceuticals PLC (JAZZ)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Jazz Pharmaceuticals PLC (JAZZ)

        Co-Founder, Chairman & CEO

        Mr. Bruce C. Cozadd

        President & COO

        Ms. Reneé D. Galá

        Headquarters

        Dublin

        FAQs for Jazz Pharmaceuticals PLC (JAZZ)

        The total asset value of Jazz Pharmaceuticals PLC (JAZZ) stood at $ 11,393 Mln as on 31-Dec-23

        The share price of Jazz Pharmaceuticals PLC (JAZZ) is $110.58 (NASDAQ) as of 12-Apr-2024 16:08 EDT. Jazz Pharmaceuticals PLC (JAZZ) has given a return of -11.84% in the last 3 years.

        Jazz Pharmaceuticals PLC (JAZZ) has a market capitalisation of $ 6,894 Mln as on 12-Apr-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Jazz Pharmaceuticals PLC (JAZZ) is 1.84 times as on 12-Apr-2024, a -0.41% premium to its peers’ median range of 3.13 times.

        The P/E (price to earnings) ratio of Jazz Pharmaceuticals PLC (JAZZ) is 18.13 times as on 12-Apr-2024.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Jazz Pharmaceuticals PLC (JAZZ) and enter the required number of quantities and click on buy to purchase the shares of Jazz Pharmaceuticals PLC (JAZZ).

        Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

        The CEO & director of Mr. Bruce C. Cozadd. is Jazz Pharmaceuticals PLC (JAZZ), and CFO & Sr. VP is Ms. Reneé D. Galá.

        The promoters of Jazz Pharmaceuticals PLC (JAZZ) have pledged 0% of the total equity as on Dec-23.

        Jazz Pharmaceuticals PLC (JAZZ) Ratios
        Return on equity(%)
        12.16
        Return on capital employed(%)
        4.51
        Debt-to-equity ratio
        1.55
        Dividend yield(%)
        --

        Yes, TTM profit after tax of Jazz Pharmaceuticals PLC (JAZZ) was $321 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $6,894.14 Mln
        • Revenue (TTM)revenue-information $3,834.20 Mln
        • Earnings (TTM) earning-information $320.68 Mln
        • Cash date-information $1,626.31 Mln
        • Total Debt info $5,796.65 Mln
        • Insider's Holding 2.82%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $110.42 - 147.14
        • Shares outstanding share-outstanding 62,345,300
        • 10 Years Aggregate:

          CFO: $7,838.78 Mln

          EBITDA: $8,672.27 Mln

          Net Profit: $2,353.42 Mln

        About The Company

        • IPO Date 01-Jun-2007
        • Co-Founder, Chairman & CEO Mr. Bruce C. Cozadd
        • President & COO Ms. Reneé D. Galá
        • Listing key-listing NASDAQ: JAZZ
        • Country Ireland
        • Headquarters headquarters Dublin
        • Website website https://www.jazzpharma.com
        • Business

          Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with...  narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.  Read more

        share-fund-plan-icon